UroGen Q3 2026 net loss narrows 96% year over year to $1.46 million

Bitget2026/11/04 13:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

UroGen Pharma’s third-quarter 2026 net loss narrowed 96% year over year to $1.46 million.
Revenue more than tripled year over year to $89 million, driven by the continued ZUSDURI launch.
ZUSDURI revenue rose 35% from the second quarter of 2026 to $68 million.
The FDA accepted the UGN-103 application for review, setting a June 14, 2027, target action date.
Full-year 2026 JELMYTO revenue guidance fell to approximately $90 million from $97 million–$101 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040800PRIMZONEFULLFEED9869829) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

UroGen Q3 2026 net loss narrows 96% year over year to $1.46 million

You may also like

Crypto prices